Larotaxel

Research use only, not for human use.

Larotaxel (XRP9881) is a taxane analogue with anticancer activity that promotes tubulin assembly and stabilizes microtubules, inducing apoptosis.

Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer. Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis. It presents the ability to cross the blood brain barrier and has a much lower affinity for P-glycoprotein 1 than Docetaxel.

——

——

——

Others

Other Targets

P-gp

——

——

156294-36-9

831.9

C45H53NO14

>98% (HPLC)

In Vitro:?DMSO : ≥ 50 mg/mL (60.10 mM)

[H][C@@]12C[C@@H]3C[C@@]33C(=O)[C@]([H])(OC(C)=O)C4=C(C)[C@@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years